New AI solution being tested at Umeå vaccine facility

A new AI solution for sustainable production is to be tested at Diamyd Medical's vaccine manufacturing facility in Umeå. It is hoped, once the solution has been refined, that it can be introduced in companies throughout Sweden.

“This represents a unique opportunity that we do not see that often in Sweden. We are happy to be working with recognised experts in both AI and sustainable production”, says Ulf Hannelius, CEO of Diamyd Medical.

Diamyd Medical is currently developing a vaccine against type 1 diabetes. This spring the publicly-listed company opened a new manufacturing facility at premises previously operated by Sobi (Swedish Orphan Biovitrum) in Ersboda in Umeå. The active substance of the test drug - GAD - will be manufactured at the facility.

Diamyd Medical, together with AI technology company MainlyAI and KTH (the Royal Institute of Technology), will collectively share SEK 13 million of funding from the Swedish Innovation Agency Vinnova for a project that will design, test and build a model for sustainable production using artificial intelligence. The project is being carried out at Diamyd Medical's new facility in Umeå, which is currently under construction.

“Through this project we will investigate how AI technologies can be used to reduce greenhouse gas emissions and how we can support decision-making and issues regarding production speed, employee well-being, sustainability goals and waste management,” says Ulf Hannelius, CEO of Diamyd Medical.

He continues:

“The goal is to develop tailor-made AI solutions for Diamyd Medical's pharmaceutical production. At the same time we want to help pave the way for climate-smart technologies and strategies that can be scaled up and applied to production facilities in various industries”.

Diamyd Medical's facility in Umeå is approximately 1,000 square meters in size and contains sterile rooms as well as laboratory and office space. Diamyd Medical is initially investing some SEK 20 million into the new facility.

For further information, please contact:

Ulf Hannelius, CEO Diamyd Medical
073-635 42 41
ulf.hannelius@diamyd.com

Relaterade länkar

diamyd.com

Kategorier

Diamyd Medical

Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Diamyd Medical moves pharmaceutical production from USA to Umeå – hires

A recruitment drive is underway at Diamyd Medical's new vaccine facility in Umeå after the company announced it is moving production of the GAD65 protein, the active substance in the diabetes vaccine Diamyd, from abroad to Sweden. “This move gives us greater control and more knowledge about our study drug”, says Maja Johansson, Site Manager in Umeå.

Key appointments being made at new diabetes vaccine facility in Umeå

Construction of Diamyd Medical's new vaccine manufacturing unit in Umeå is now underway, with a number of key roles being actively recruited to help staff the new facility. Newly-appointed site manager Maja Johansson is responsible for establishing the process for the production of GAD, the active substance in the study drug Diamyd.

We grow ideas that can change the world